Added to YB: 2025-11-12
Pitch date: 2025-11-05
GRFS [neutral]
Grifols, S.A.
+3.82%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
Market Cap
EUR 6.7B
Pitch Price
EUR 10.74
Price Target
N/A
Dividend
2.72%
EV/EBITDA
9.86
P/E
20.19
EV/Sales
2.39
Sector
Biotechnology
Category
turnaround
Medtech, telcos and AI fears - Grifols (GRFS)
GRFS (quick overview): Q3 showed operational progress with strong immunoglobulin performance but weak albumin/China pricing. EBITDA above consensus yet FCF remains anemic. Leverage stuck >5x EBITDA despite improved cash flow. 2027 debt maturity cliff unaddressed. Mgmt prioritizes dividends over deleveraging. Recovery remains cosmetic amid execution risk.
Read full article (2 min)